KRAS and ovarian carcinoma: Of the potential pathway components in the literature, K-Ras mutation, which occurred in 231-BR cells and constitutively activates B-Raf, is found in lung, cervical and ovarian carcinomas [35], [36], [37]; renal carcinomas demonstrate both K-Ras mutation and amplification [38], [39].